New PET tracer could spot hidden heart scarring in rare amyloidosis
NCT ID NCT07549841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special radioactive tracer called [68Ga]Ga-FAPI-46 for PET scans in 40 people with transthyretin cardiac amyloidosis (ATTR-CM), a condition where abnormal proteins build up in the heart. The goal is to see if this scan can measure scar-like activity in the heart muscle and help doctors tell how advanced the disease is or if it's getting worse. If it works, it could lead to better staging and personalized treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-FAPI-46 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors better stage the disease and identify which patients are worsening, leading to more personalized treatment.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The tracer's ability to predict progression needs further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Nantes
Nantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact